-
The explosive procurement of domestic medical equipment has brought a superimposed effect, a main line of innovative drugs that benefit from the relaxation of policies
Time of Update: 2022-11-14
Therefore, the hemp essence drug market shows the characteristics of few players and a good competitive pattern, and has long been occupied by four major enterprises in the main market share, namely: Hengrui Pharmaceutical, Enhua Pharmaceutical, Renfu Pharmaceutical, and Yangtze River Pharmaceutical.
-
GLP-1: It's just the beginning
Time of Update: 2022-11-14
"Insulin Collective Response Strategy from a Company Perspective"Imported GLP-1 patternImported GLP-1 patternAccording to the PDB drug comprehensive database data of China Pharmaceutical Industry Information Center, a total of 7 GLP-1 have sales data in domestic sample pharmacies.
-
Innovative medicine "The Hunger Games": no champions, only survivors
Time of Update: 2022-11-14
Source: Official website of the State Medical Products AdministrationEven, if high investment is still required in the follow-up, and the capital market is expected to decrease, the competitive environment changes, and the drug does not have time to be commercialized, its value will face "destruction".
-
The 20 billion market is "full of smoke", and the osteoporosis research and development competition is about to start! Who can dominate?
Time of Update: 2022-11-05
There was a great opportunity for treatment in front of me, but I didn't cherish it. There was a great opportunity for treatment in front of me, but I didn't cherish it. I didn't regret it until I mis
-
Tumor genetic testing into medical insurance, can the spring of NGS enterprises come?
Time of Update: 2022-11-05
PCR , FISH, IHC and NGS four technologiesAccording to the Global Times, Zhou Jun, deputy chief physician of the Department of Gastroenterology and Oncology of Peking University Cancer Hospital, introduced: At present, the tumor genetic testing projects reimbursed by Beijing medical insurance only include traditional technologies such as FISH and PCR, and the general cost of testing a gene does not exceed 500 yuan, even if it is packaged to test 10 genes, it is only 5,000 yuan.
-
Pharmaceutical giants withdraw from the cell therapy alliance
Time of Update: 2022-11-05
On the morning of October 25, British biotechnology company Adaptimmune released news that GlaxoSmithKline (GSK) abandoned its NY-ESO and PRAME projects, and GlaxoSmithKline's partner Lyell also announced on the 24th that GlaxoSmithKline has withdrawn from the Cell Therapy 2.
-
China's orphan drug research and development: there is no shortage of talent and technology, and there is a lack of policies
Time of Update: 2022-11-05
The release of the "36 Innovative Opinions" in October 2017 gives us hope for the development of orphan drugs in China, which is an important milestone in the development of Chinese medicine. In the p
-
Tens of billions of dollars JAK inhibitor market, Pfizer Xeljanz is gone, which new forces will rise?
Time of Update: 2022-11-05
However, it is worth mentioning that Pfizer second-generation JAK1 inhibitor abxertinib has been approved in China in April this year for refractory moderate to severe AD adult patients who do not respond well to other systemic treatments (such as hormones or biologics) or are not suitable for the above treatment, and have also passed the preliminary review of medical insurance.
-
A large number of pharmaceutical companies have successfully financed funds, which will accelerate product innovation and commercialization
Time of Update: 2022-11-05
In recent years, cell and gene therapy has become one of the most eye-catching emerging areas in the global biotechnology field, and as a result, it continues to receive significant investment from investors and biopharmaceutical companies.
-
The wave of digitalization of pharmaceutical companies is surging, and hidden big data has run out of new commercial scenarios
Time of Update: 2022-11-05
The value of big data in pharmaceutical circulation is mainly reflected in cost reduction and efficiency improvement, business opportunity exploration and risk early warning.
-
The legendary creature CAR-T sells well in Europe and the United States! Domestic CAR-T is still involutional! "Going to sea" through the winter?
Time of Update: 2022-11-05
October 2017 Targeting CD19October 2017The FDA approved Gilead's Yescarta for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) who have previously received second- or multi-line systemic therapy.
-
Gilead advances next-generation CAR-T therapies in partnership with cell therapy companies
Time of Update: 2022-11-05
Gilead announced that its subsidiary Kite has partnered with Refuge, a company dedicated to developing smart cell therapies using genetic engineering technology Biotechnologies entered into a global licensing agreement, and Kite received an exclusive license to Refuge's intellectual property for blood cancer treatment, as well as a synthetic gene expression library for that indication.
-
Hua Medicine New Diabetes Drug Officially Launched to Achieve First Prescription Sales!
Time of Update: 2022-11-05
Hua Tangning ® is an innovative drug developed by Hua Medicine using the operation model of "combining East and West, joint innovation, sharing and win-win", the industry believes that the product is approved for marketing in China, which means becoming the first first-in-class new drug listed in China, which will provide new treatment options for patients with type 2 diabetes in China.
-
First-in-class: Zentalis initiates its first collaborative project with Pfizer to develop the selective Wee1 inhibitor ZN-c3
Time of Update: 2022-11-05
Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer ZN-d5 is an oral selective inhibitor of B-cell lymphoma 2 (BCL-2) that was originally developed for the treatment of hematologic malignancies and related diseases.
-
Experts point to how innovative market access agreements will be applied to high-value drugs in China in the future
Time of Update: 2022-11-05
As the world embraces rapid medical innovations, it is also under pressure to pay high fees. The payment problem of breakthrough innovative drugs has also become a global challenge. Especially under t
-
The market value of the vaccine brother plummeted by 20 billion, and the exclusive market of 100 billion yuan was "precarious"
Time of Update: 2022-11-05
On October 27, the opening stock price of vaccine giant Zhifei Biologics fell rapidly, falling by more than 17% at one point. As of midday, Zhifei Biotech's share price closed at 82. 49 yuan per share
-
Novartis 2022Q3 China grows by 5%, Innovative Drugs and Sandoz grow 4%
Time of Update: 2022-11-05
Novartis maintains growth momentum and confirms FY'22 Group guidance Source: Novartis financial reportIn addition, Pluvicto (lutetium lu 177 vipivotide), a targeted radioisotope therapy for the treatment of prostate cancer, has been approved in the United States and Europe tetraxetan), third-quarter sales of $80 million.
-
66 varieties began to be collected, including biological agents (with list)
Time of Update: 2022-11-05
The alliance of 15 provinces including Jiangxi and Hebei Province will purchase 15 and 51 varieties respectively, involving oxacillin, ranitidine, tacrolimus, human growth hormone, etc. 51 varieties b
-
"Escaping" the European market, the commercialization of gene therapy
Time of Update: 2022-11-05
Gene therapies for prevalent diseases in Europe – the perfect storm of economic sustainability?； pharmaphorum In addition to national market access challenges, especially in ultra-rare areas, manufacturers must also go through the EU's cross-border reimbursement route.
-
In the field of breast cancer, AZ has laid down a "sky and earth net": ADC, oral SERD, AKT inhibitors...
Time of Update: 2022-11-05
Yesterday, AZ announced the next generation of oral SERD Camizestrant Treatment of stage II SERENA-2 in patients with estrogen receptor-positive (ER+) locally progressive or metastatic breast cancer The study met the primary endpoint.
